Gaucher cells demonstrate a distinct macrophage phenotype and resemble alternatively activated macrophages.

Although the existence of anti-inflammatory alternatively activated macrophages (aamphi) has been accepted widely based on in vitro studies, their in vivo location, phenotype, and function still are debated. Gaucher disease (GD) is caused by a genetic deficiency in the lysosomal enzyme glucocerebrosidase and is characterized by accumulation of glycosphingolipids in so-called Gaucher cells (GCs). By using immunohistochemical analysis, we investigated whether this results in an aamphi phenotype. GCs are macrophage-like cells, expressing acid phosphatase, CD68, CD14, and HLA class II, but not CD11b, CD40, or dendritic cell markers. GCs show infrequent immunoreactivity for mannose receptor GCs did not express proinflammatory cytokines such as tumor necrosis factor alpha and monocyte chemoattractant protein 1, but did express the aamphi markers CD163, CCL18, and interleukin-1 receptor antagonist. Furthermore, CD36 and signal receptor protein alpha, involved in lipid uptake, also were observed on GCs. Thus, GCs represent a distinctive population of myeloid cells that resemble aamphi but differ from previously described in vitro aamphi.

[1]  D. Witte,et al.  Viable mouse models of acid beta-glucosidase deficiency: the defect in Gaucher disease. , 2003, The American journal of pathology.

[2]  D. Gemsa,et al.  Shift toward an alternatively activated macrophage response in lungs of NO2-exposed rats. , 2003, American journal of respiratory cell and molecular biology.

[3]  Judith E. Allen,et al.  Macrophages in chronic type 2 inflammation have a novel phenotype characterized by the abundant expression of Ym1 and Fizz1 that can be partly replicated in vitro. , 2003, Immunology letters.

[4]  A. Ullrich,et al.  Dominant Negative Form of Signal-regulatory Protein-α (SIRPα/SHPS-1) Inhibits Tumor Necrosis Factor-mediated Apoptosis by Activation of NF-κB* , 2002, The Journal of Biological Chemistry.

[5]  P. Allavena,et al.  Macrophage polarization: tumor-associated macrophages as a paradigm for polarized M2 mononuclear phagocytes. , 2002, Trends in immunology.

[6]  M. Stollenwerk,et al.  Decreased inducibility of TNF expression in lipid-loaded macrophages , 2002, BMC Immunology.

[7]  T. Lawrence,et al.  Anti-inflammatory lipid mediators and insights into the resolution of inflammation , 2002, Nature Reviews Immunology.

[8]  J. Dreier,et al.  Only the soluble form of the scavenger receptor CD163 acts inhibitory on phorbol ester‐activated T‐lymphocytes, whereas membrane‐bound protein has no effect , 2002, FEBS letters.

[9]  S. Matsuda,et al.  SHPS‐1, a multifunctional transmembrane glycoprotein , 2002, FEBS letters.

[10]  R. Proia,et al.  Systemic inflammation in glucocerebrosidase-deficient mice with minimal glucosylceramide storage. , 2002, The Journal of clinical investigation.

[11]  P. De Baetselier,et al.  Differential expression of FIZZ1 and Ym1 in alternatively versus classically activated macrophages , 2002, Journal of leukocyte biology.

[12]  P. H. Petersen,et al.  Soluble CD163: a marker molecule for monocyte/macrophage activity in disease , 2002, Scandinavian journal of clinical and laboratory investigation. Supplementum.

[13]  S. Goerdt,et al.  Alternatively Activated Antigen-Presenting Cells: Molecular Repertoire, Immune Regulation, and Healing , 2001, Skin Pharmacology and Physiology.

[14]  Eric J. Brown,et al.  Bidirectional Negative Regulation of Human T and Dendritic Cells by CD47 and Its Cognate Receptor Signal-Regulator Protein-α: Down-Regulation of IL-12 Responsiveness and Inhibition of Dendritic Cell Activation1 , 2001, The Journal of Immunology.

[15]  A. Ullrich,et al.  Signal-regulatory protein alpha (SIRPalpha) but not SIRPbeta is involved in T-cell activation, binds to CD47 with high affinity, and is expressed on immature CD34(+)CD38(-) hematopoietic cells. , 2001, Blood.

[16]  Constantin E. Orfanos,et al.  Alternative versus Classical Activation of Macrophages , 2000, Pathobiology.

[17]  V. Barak,et al.  Cytokines in Gaucher's disease. , 1999, European cytokine network.

[18]  H. Cryer,et al.  Macrophage TNF mRNA expression induced by LPS is regulated by sphingomyelin metabolites. , 1999, Shock.

[19]  P. Fredman Sphingolipids and cell signalling , 1998, Journal of Inherited Metabolic Disease.

[20]  A. Namboodiri,et al.  Sphingomyelinase and Ceramide Stimulate the Expression of Inducible Nitric-oxide Synthase in Rat Primary Astrocytes* , 1998, The Journal of Biological Chemistry.

[21]  C. Howard,et al.  Cloning of two members of the SIRPα family of protein tyrosine phosphatase binding proteins in cattle that are expressed on monocytes and a subpopulation of dendritic cells and which mediate binding to CD4 T cells , 1998, European journal of immunology.

[22]  G. Pastores,et al.  7 Pathological features , 1997 .

[23]  C. Hollak,et al.  Elevated levels of M-CSF, sCD14 and IL8 in type 1 Gaucher disease. , 1997, Blood cells, molecules & diseases.

[24]  C. Hollak,et al.  Plasma tumor necrosis factor-a (TNF-a) levels in Gaucher disease. , 1996, Biochimica et biophysica acta.

[25]  A. Florena,et al.  Immunophenotypical comparison of Gaucher's and pseudo‐Gaucher cells , 1996, Pathology international.

[26]  A. V. van Zonneveld,et al.  Cloning of a cDNA Encoding Chitotriosidase, a Human Chitinase Produced by Macrophages (*) , 1995, The Journal of Biological Chemistry.

[27]  J. Aerts,et al.  Individualised low-dose alglucerase therapy for type 1 Gaucher's disease , 1995, The Lancet.

[28]  R. Brady,et al.  Modifying exogenous glucocerebrosidase for effective replacement therapy in Gaucher disease , 1994, Journal of Inherited Metabolic Disease.

[29]  P. Buckley,et al.  Macrophages (histiocytes) in various reactive and inflammatory conditions express different antigenic phenotypes. , 1992, Human pathology.

[30]  E. Ginns,et al.  Animal model of Gaucher's disease from targeted disruption of the mouse glucocerebrosidase gene , 1992, Nature.

[31]  J. Dambrosia,et al.  Replacement therapy for inherited enzyme deficiency--macrophage-targeted glucocerebrosidase for Gaucher's disease. , 1991, The New England journal of medicine.

[32]  Boris Bleijlevens,et al.  Marked elevation of the chemokine CCL18/PARC in Gaucher disease: a novel surrogate marker for assessing therapeutic intervention. , 2004, Blood.

[33]  William,et al.  The Metabolic and Molecular Bases of Inherited Disease (Scriver, C. R., Beaudet, A. L., Sly, W. S., Valle, D., Childs, B., Kinzler, K. W., and Vogelstein, B., eds., 8th ed., McGraw-Hill, New-York, 2001, 7012 p., $550.00) , 2004, Biochemistry (Moscow).

[34]  A. Ullrich,et al.  Dominant negative form of signal-regulatory protein-alpha (SIRPalpha /SHPS-1) inhibits tumor necrosis factor-mediated apoptosis by activation of NF-kappa B. , 2003, The Journal of biological chemistry.

[35]  Peter Tontonoz,et al.  Reciprocal regulation of inflammation and lipid metabolism by liver X receptors , 2003, Nature Medicine.

[36]  S. Gordon Alternative activation of macrophages , 2003, Nature Reviews Immunology.

[37]  A. Mantovani,et al.  IL-6: a regulator of the transition from neutrophil to monocyte recruitment during inflammation. , 2003, Trends in immunology.

[38]  G. Petrusevska,et al.  Immunohistochemical and ultrastructural features of Gaucher's cells--five case reports. , 2001, Acta medica Croatica : casopis Hravatske akademije medicinskih znanosti.

[39]  N. Rushton,et al.  Pro-inflammatory cytokines and the pathogenesis of Gaucher's disease: increased release of interleukin-6 and interleukin-10. , 1997, QJM : monthly journal of the Association of Physicians.

[40]  G. Pastores Gaucher's Disease. Pathological features. , 1997, Bailliere's clinical haematology.

[41]  E Claassen,et al.  Detection of human cytokines in situ using antibody and probe based methods. , 1995, Journal of immunological methods.

[42]  J. M. Aerts,et al.  Differential effects of enzyme supplementation therapy on manifestations of type 1 Gaucher disease. , 1997, The American journal of medicine.